Literature DB >> 12505247

Evaluating surrogate endpoints.

Michael D Hughes1.   

Abstract

Mesh：

Year:  2002        PMID： 12505247     DOI： 10.1016/s0197-2456(02)00264-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN： 0197-2456


× No keyword cloud information.
  7 in total

Review 1.  Biomarkers and surrogate markers: an FDA perspective.

Authors:  Russell Katz
Journal:  NeuroRx       Date:  2004-04

2.  Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective.

Authors:  Mary L Bouxsein; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

3.  Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).

Authors:  R Oyomopito; M P Lee; P Phanuphak; P L Lim; R Ditangco; J Zhou; T Sirisanthana; Y M A Chen; S Pujari; N Kumarasamy; S Sungkanuparph; C K C Lee; A Kamarulzaman; S Oka; F J Zhang; C V Mean; T Merati; G Tau; J Smith; P C K Li
Journal:  HIV Med       Date:  2010-03-21       Impact factor: 3.180

Review 4.  The perils of surrogate endpoints.

Authors:  William S Weintraub; Thomas F Lüscher; Stuart Pocock
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

Review 5.  Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.

Authors:  Qian Shi; Daniel J Sargent
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

6.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

7.  CD4 trajectory adjusting for dropout among HIV-positive patients receiving combination antiretroviral therapy in an East African HIV care centre.

Authors:  Agnes N Kiragga; Judith J Lok; Beverly S Musick; Ronald J Bosch; Ann Mwangi; Kara K Wools-Kaloustian; Constantin T Yiannoutsos
Journal:  J Int AIDS Soc       Date:  2014-08-14       Impact factor: 5.396
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.